Co-Diagnostics (HAM:C970) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:C970 Co-Diagnostics Inc HAM:C970
63 GF Score
Price €5.55
GF Value €4.78
! 6 Warning Signs
View Full Analysis

What is Co-Diagnostics Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

HAM:C970
63GF Score
Co-Diagnostics Inc HAM:C970
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Co-Diagnostics (HAM:C970) Overvalued in 2026?

Based on GuruFocus' analysis, Co-Diagnostics stock appears to be overvalued. The current stock price of €5.55 is trading 16.1% above its estimated GF Value™ of €4.78.

Key valuation signals for HAM:C970:

  • Interest Received:
  • GF Value™: €4.78 vs. price of €5.55 (16.1% above fair value)
  • GF Score™: 63/100 with 6 warning signs

No single metric tells the full story. See the HAM:C970 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Co-Diagnostics Business Description

Other Exchanges CODX:USA0A50:UK
Address 2401 S. Foothill Drive, Suite D, Salt Lake City, UT, USA, 84109
Co-Diagnostics Inc is a molecular diagnostics company. The company develops, manufactures, licenses, and commercializes reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), including molecular tools for detection of infectious diseases. CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and others. The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.
63GF Score

Get the complete analysis for HAM:C970

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.55
Price
€4.78
GF Value